Characterization of two constitutively active prolactin receptor variants in a cohort of 95 women with multiple breast fibroadenomas

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 1, 2010, Pages 271-279

  Courtillot, Carine ^a,b   Chakhtoura, Zeina ^a,b   Bogorad, Roman ^b,c   Genestie, Catherine ^a   Bernichtein, Sophie ^b,c   Badachi, Yasmina ^a   Janaud, Gilbert ^a   Akakpo, Jean Pierre ^a   Bachelot, Anne ^a,b,d   Kuttenn, Frédérique ^a,b,c   Goffin, Vincent ^b,c   Touraine, Philippe ^a,b,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROLACTIN RECEPTOR;

ADULT; ANAMNESIS; ARTICLE; BREAST FIBROADENOMA; BREAST SURGERY; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; ECHOMAMMOGRAPHY; FEMALE; GENE SEQUENCE; GENETIC CODE; GENETIC VARIABILITY; GONAD FUNCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL;

PHYLLODES;

EID: 75149182694     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1494     Document Type: Article

References (33)

1. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA 1998 Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocr Rev 19:225-268
2. Neville MC, McFadden TB, Forsyth I 2002 Hormonal regulation of mammary differentiation and milk secretion. J Mammary Gland Biol Neoplasia 7:49-66
3. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE 1999 Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91:629-634
4. Tworoger SS, Sluss P, Hankinson SE 2006 Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66:2476-2482
5. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, Nicolas A, Trivin C, Postel-Vinay MC, Kuttenn F, Kelly PA 1998 Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 83:667-674
6. Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Törnell J 1997 Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 100:2744-2751
7. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA 2003 Prolactin induces ERα-positive and ERαa-negative mammary cancer in transgenic mice. Oncogene 22: 4664-4674
8. Ormandy CJ, Naylor M, Harris J, Robertson F, Horseman ND, Lindeman GJ, Visvader J, Kelly PA 2003 Investigation of the transcriptional changes underlying functional defects in the mammary glands of prolactin receptor knockout mice. Recent Prog Horm Res 58:297-323
9. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, Edery M, Brousse N, Babinet C, Binart N, Kelly PA 1997 Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 11:167-178
10. Horseman ND, Zhao W, Montecino-Rodriguez E, Tanaka M, Nakashima K, Engle SJ, Smith F, Markoff E, Dorshkind K 1997 Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 16:6926-6935
11. Liu X, Gallego MI, Smith GH, Robinson GW, Hennighausen L 1998 Functional rescue of Stat5a-null mammary tissue through the activation of compensating signals including Stat5b. Cell Growth Differ 9:795-803
12. Canbay E, Degerli N, Gulluoglu BM, Kaya H, Sen M, Bardakci F 2004 Could prolactin receptor gene polymorphism play a role in pathogenesis of breast carcinoma? Curr Med Res Opin 20:533-540
13. Vaclavicek A, Hemminki K, Bartram CR, Wagner K, Wappenschmidt B, Meindl A, Schmutzler RK, Klaes R, Untch M, Burwinkel B, Försti A 2006 Association of prolactin and its receptor gene regions with familial breast cancer. J Clin Endocrinol Metab 91:1513-1519
14. Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, Pike MC, Altshuler D, Hirschhorn JN, Henderson BE, Stram DO 2007 A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the Multiethnic Cohort.BMC Med Genet 8:72
15. Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P 2008 Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci USA 105:14533-14538
16. Hughes LE, Mansel RE, Webster DJT 2000 Benign disorders and diseases of the breast - concepts and clinical management. 2nd ed. Hughes LE, Mansel RE, Webster DJT, eds. Philadelphia: W. B. Saunders Ltd.; P21-34; chap 3
17. Harvey JM, Clark GM, Osborne CK, Allred DC 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474-1481
18. Bernichtein S, Jeay S, Vaudry R, Kelly PA, Goffin V 2003 New homologous bioassays for human lactogens show that agonism or antagonism of various analogs is a function of assay sensitivity. Endocrine 20:177-190
19. Duflos C, Plu-Bureau G, Thibaud E, Kuttenn F 2004 Breast diseases in adolescents. Endocr Dev 7:183-196
20. Courtillot C, Plu-Bureau G, Binart N, Balleyguier C, Sigal-Zafrani B, Goffin V, Kuttenn F, Kelly PA, Touraine P 2005 Benign breast diseases. J Mammary Gland Biol Neoplasia 10:325-335
21. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton 3rd LJ, Visscher DW 2005 Benign breast disease and the risk of breast cancer. New Engl J Med 353:229-237
22. Dupont WD, Page DL, Parl FF, Vnencak-Jones CL, Plummer Jr WD, Rados MS, Schuyler PA 1994 Long term risk of breast cancer in women with fibroadenoma. N Engl J Med 331:10-15
23. Sitruk-ware LR, Sterkers N, Mowszowicz I, Mauvais-Jarvis P 1977 Inadequate corpus luteal function in women with benign breast diseases. J Clin Endocrinol Metab 44:771-774
24. Parlati E, Travaglini A, Liberale I, Menini E, Dell'Aqua S 1988 Hormonal profile in benign breast disease. Endocrine status of cyclical mastalgia patients. J Endocinol Invest 11:679-683
25. Walsh PV, McDicken IW, Bulbrook RD, Moore JW, Taylor WH, George WD 1984 Serum oestradiol-17β and prolactin concentrations during the luteal phase in women with benign breast disease. Eur J Cancer Clin Oncol 20:1345-1351
26. Kumar S, Mansel RE, Scanlon MF, Hughes LE, Edwards CA, Woodhead JS, Newcombe RG 1984 Altered responses of prolactin, luteinizing hormone and follicle stimulating hormone secretion to thyrotrophin releasing hormone/gonadotrophin releasing hormone stimulation in cyclical mastalgia. Br J Surg 71:870-873
27. Kumar S, Mansel RE, Hughes LE, Woodhead JS, Edwards CA, Scanlon MF, Newcombe RG 1984 Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease. Cancer 53:1311-1315
28. Parlati E, Polinari U, Salvi G, Giorlandino C, Liberale I, Fiorella G, Dell'Acqua S 1987 Bromocriptine for treatment of benign breast disease. A double-blind clinical trial versus placebo. Acta Obstet Gynecol Scand 66:483-488
29. Tavassoli FA 1999 Biphasic tumors. Pathology of the breast. 2nd ed. Stamford, CT: Appleton Lange; 571-631
30. Kocová L, Skálová A, Fakan F, Rousarová M 1998 Phyllodes tumor of the breast: Immunohistochemical study of 37 tumors using MIB1 antibody. Pathol Res Pract 94:97-104
31. Stuart-Harris R, Caldas C, Pinder SE, Pharoah P 2008 Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32825 patients. Breast 17:323-334
32. Witte F, Hönig A, Mirecka J, Schauer A 1999 Cystosarcoma phyllodes of the breast: prognostic significance of proliferation and apoptosis associated genes. Anticancer Res 19:3355-3359
33. Goffin V, Touraine P, Culler MD, Kelly PA 2006 Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab 2:571-581